{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:17:33Z","timestamp":1760242653393,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172969"],"award-info":[{"award-number":["81172969"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Anthrax toxin is the major virulence factor produced by Bacillus anthracis. Protective antigen (PA) is the key component of the toxin and has been confirmed as the main target for the development of toxin inhibitors. The inhibition of the binding of PA to its receptor, capillary morphogenesis protein-2 (CMG2), can effectively block anthrax intoxication. The recombinant, soluble von Willebrand factor type A (vWA) domain of CMG2 (sCMG2) has demonstrated potency against anthrax toxin. However, the short half-life of sCMG2 in vivo is a disadvantage for its development as a new anthrax drug. In the present study, we report that HSA-CMG2, a protein combining human serum albumin (HSA) and sCMG2, produced in the Pichia pastoris expression system prolonged the half-life of sCMG2 while maintaining PA binding ability. The IC50 of HSA-CMG2 is similar to those of sCMG2 and CMG2-Fc in in vitro toxin neutralization assays, and HSA-CMG2 completely protects rats from lethal doses of anthrax toxin challenge; these same challenge doses exceed sCMG2 at a sub-equivalent dose ratio and overwhelm CMG2-Fc. Our results suggest that HSA-CMG2 is a promising inhibitor of anthrax toxin and may contribute to the development of novel anthrax drugs.<\/jats:p>","DOI":"10.3390\/toxins8010028","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T11:19:41Z","timestamp":1453288781000},"page":"28","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-3109","authenticated-orcid":false,"given":"Liangliang","family":"Li","sequence":"first","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"},{"name":"Center for Disease Control and Prevention of Navy, Beijing 101113, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yin","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayong","family":"Dong","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Fu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","article-title":"Systematic review: A century of inhalational anthrax cases from 1900 to 2005","volume":"144","author":"Holty","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0014-5793(02)03609-8","article-title":"Anthrax toxin: A tripartite lethal combination","volume":"531","author":"Ascenzi","year":"2002","journal-title":"FEBS Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","article-title":"Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor","volume":"280","author":"Duesbery","year":"1998","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1073\/pnas.79.10.3162","article-title":"Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells","volume":"79","author":"Leppla","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/iai.47.1.306-310.1985","article-title":"Effects of anthrax toxin components on human neutrophils","volume":"47","author":"Friedlander","year":"1985","journal-title":"Infect. Immun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1099\/00221287-138-3-543","article-title":"Serum protease cleavage of bacillus anthracis protective antigen","volume":"138","author":"Ezzell","year":"1992","journal-title":"J. Gen. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1073\/pnas.0431098100","article-title":"Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor","volume":"100","author":"Scobie","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/432731","article-title":"A soluble receptor decoy protects rats against anthrax lethal toxin challenge","volume":"192","author":"Scobie","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1083\/jcb.200507067","article-title":"Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis","volume":"172","author":"Abrami","year":"2006","journal-title":"J. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1242\/jcs.114.15.2755","article-title":"Differential gene expression during capillary morphogenesis in 3D collagen matrices regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling","volume":"114","author":"Bell","year":"2001","journal-title":"J. Cell Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/toxins5010001","article-title":"The receptors that mediate the direct lethality of anthrax toxin","volume":"5","author":"Liu","year":"2013","journal-title":"Toxins"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/341902","article-title":"Management of anthrax","volume":"35","author":"Bartlett","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev.micro.55.1.647","article-title":"Anthrax","volume":"55","author":"Mock","year":"2001","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/35102660","article-title":"Tackling anthrax","volume":"414","author":"Friedlander","year":"2001","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1517\/17460441.2014.877884","article-title":"Designing inhibitors of anthrax toxin","volume":"9","author":"Nestorovich","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1128\/AAC.01294-08","article-title":"Efficient neutralization of antibody-resistant forms of anthrax toxin by a soluble receptor decoy inhibitor","volume":"53","author":"Sharma","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Thomas, D., Naughton, J., Cote, C., Welkos, S., Manchester, M., and Young, J.A.T. (2012). Delayed toxicity associated with soluble anthrax toxin receptor decoy-Ig fusion protein treatment. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034611"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/AAC.00592-10","article-title":"Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax","volume":"55","author":"Wycoff","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1073\/pnas.062160399","article-title":"Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen","volume":"99","author":"Cunningham","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Abrami, L., Bischofberger, M., Kunz, B., Groux, R., and van der Goot, F.G. (2010). Endocytosis of the anthrax toxin is mediated by clathrin, actin and unconventional adaptors. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000792"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4161\/mabs.3.6.17621","article-title":"Antibodies for biodefense","volume":"3","author":"Froude","year":"2011","journal-title":"MAbs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10930-008-9137-0","article-title":"A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax","volume":"27","author":"Vuyisich","year":"2008","journal-title":"Protein J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Xi, Y., Wu, X., Gao, L., Shao, Y., Peng, H., Chen, H., Chen, H., Hu, X., and Yue, J. (2014). Improving the anti-toxin abilities of the CMG2-Fc fusion protein with the aid of computational design. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104674"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: From bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol. Aspects Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1074\/jbc.M700820200","article-title":"Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin","volume":"282","author":"Muller","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jbiotec.2007.04.016","article-title":"Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation","volume":"131","author":"Zhao","year":"2007","journal-title":"J. Biotechnol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10529-011-0793-3","article-title":"Fusion of HSA influences tnf-aneutralizing activity of shTNFRs","volume":"34","author":"Zhan","year":"2012","journal-title":"Biotechnol. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/protein\/gzt044","article-title":"An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action","volume":"26","author":"Berger","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pep.2012.05.003","article-title":"Expression, purification and characterization of recombinant human interleukin-2-serum albumin (rhiL-2-HSA) fusion protein in pichia pastoris","volume":"84","author":"Lei","year":"2012","journal-title":"Protein Expr. Purif."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for igg catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: New developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_34","first-page":"652","article-title":"Expression, purification and characterization of the recombinant anthrax protective antigen","volume":"20","author":"Xu","year":"2004","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pep.2013.02.012","article-title":"Secretory expression and efficient purification of recombinant anthrax toxin lethal factor with full biological activity in E. coli","volume":"89","author":"Liu","year":"2013","journal-title":"Protein Expr. Purif."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cai, C., Che, J., Xu, L., Guo, Q., Kong, Y., Fu, L., Xu, J., Cheng, Y., and Chen, W. (2011). Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020646"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/8\/1\/28\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:17:57Z","timestamp":1760210277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/8\/1\/28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1]]}},"alternative-id":["toxins8010028"],"URL":"https:\/\/doi.org\/10.3390\/toxins8010028","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2016,1,20]]}}}